AGENDA

DAY 1 — TUESDAY, DECEMBER 2

7:00 A.M.  REGISTRATION

8:00 A.M.  Welcome and Rationale for Conference
Conference Chair: Clifford Rosen, M.D. — Maine Medical Center Research Institute

SESSION 1: THE CHALLENGES—HOW DO WE EVALUATE AND APPLY EVIDENCE FOR PRIMARY CARE DECISION MAKING?

8:10 A.M.  Principles for Evaluating Evidence
Barry S. Kramer, M.D., M.P.H. — National Cancer Institute (NCI), National Institutes of Health (NIH)

8:40 A.M.  Translating Evidence into Guidelines
Victor M. Montori, M.D. — Mayo Clinic

9:10 A.M.  Revised Criteria for National Guidelines Clearinghouse
Mary Nix, M.S. — Agency for Healthcare Research and Quality

9:30 A.M.  BREAK

9:45 A.M.  Development of Endocrine Society Guidelines
Michael F. Holick, M.D., Ph.D. — Boston University School of Medicine

10:15 A.M.  Applying Systematic Reviews to Dietary Reference Intakes: Vitamin D as a Case Study
Patsy M. Brannon, Ph.D., M.S. — Cornell University

10:45 A.M.  U.S. Preventive Services Task Force: Screening for Vitamin D Deficiency
Michael L. LeFevre, M.D., M.S.P.H. — University of Missouri

11:15 A.M.  Panel: Perspectives on Evaluating Evidence in Primary Care Context
Moderator: Paul M. Coates, Ph.D. — Office of Dietary Supplements (ODS), NIH
• Robert P. Heaney, M.D. — Creighton University
• Gordon Guyatt, M.D., M.Sc., F.R.C.P.C., O.C. — McMaster University
• Edward L. Giovannucci, M.D., Sc.D. — Harvard School of Public Health
• Roger Bouillon, M.D., Ph.D., F.R.C.P. — KU Leuven, Belgium

Open Discussion: Panel and Audience

12:15 P.M.  LUNCH (ON YOUR OWN)
SESSION 2: WHAT IS THE VIEW FROM THE FRONT LINES?

1:30 P.M. The Vitamin D Landscape
Clifford Rosen, M.D. — Maine Medical Center Research Institute

1:45 P.M. Panel: What Is the Vitamin D Experience?
Moderator: Clifford Rosen, M.D. — Maine Medical Center Research Institute
- Ravi I. Thadhani — M.D., M.P.H. — Harvard University and Massachusetts General Hospital
- Peter S. Millard, M.D., Ph.D. — Seaport Community Health Center
- Sylvia B. Rowe, M.A. — SR Strategy, LLC.

Open Discussion: Panel and Audience

SESSION 3: THE UNCERTAINTIES—HOW DO WE THINK ABOUT RISK OF NUTRITIONAL INADEQUACY?

2:15 P.M. Requirement Distributions and Clinical Practice
Alicia L. Carriquiry, Ph.D., M.Sc. — Iowa State University

2:45 P.M. BREAK

3:00 P.M. Groups at Risk: Is Lower Serum 25(OH)D Always a Concern?
Bonny Specker, Ph.D. — South Dakota State University

3:30 P.M. African American Case Study: Serum 25(OH)D and Bone Health
John F. Aloia, M.D. — Winthrop University Hospital and SUNY Stony Brook

4:00 P.M. African American Case Studies: Genetic Variants
- Perspective 1
  Ravi I. Thadhani, M.D., M.P.H. — Harvard University and Massachusetts General Hospital
- Perspective 2
  Roger Bouillon, M.D., Ph.D., F.R.C.P. — KU Leuven, Belgium

Open Discussion: Panel and Audience

5:00 P.M. ADJOURN
DAY 2 — WEDNESDAY, DECEMBER 3

SESSION 4: THE UNCERTAINTIES—WHAT DO WE KNOW ABOUT VITAMIN D INTAKE AND SUPPLEMENT USE?

7:30 A.M.  REGISTRATION

8:00 A.M.  Current Exposure to Vitamin D: Food, Food Fortification, and Supplements
  *Valerie Tarasuk, Ph.D.* — University of Toronto

8:30 A.M.  Changes in Serum 25(OH)D Concentrations with Amount and Nature of Intake
  *Sue A. Shapses, Ph.D., R.D.* — Rutgers University

9:00 A.M.  Possible Adverse Consequences of Higher Vitamin D Status: Emerging Evidence from Observational Studies
  *Demetrius Albanes, M.D.* — NCI, NIH

9:30 A.M.  Sessions 3 & 4: Joint Panel Discussion—Balancing Risk and Intervention
  Moderator: *Susan T. Mayne, Ph.D.* — Yale School of Public Health
  - *Valerie Tarasuk, Ph.D.* — University of Toronto
  - *Sue A. Shapses, Ph.D., R.D.* — Rutgers University
  - *Demetrius Albanes, M.D.* — NCI, NIH
  - *Bonny Specker, Ph.D.* — South Dakota State University
  - *John F. Aloia, M.D.* — Winthrop University Hospital and SUNY Stony Brook
  - *Ravi I. Thadhani, M.D., M.P.H.* — Harvard University and Massachusetts General Hospital
  - *Roger Bouillon, M.D., Ph.D., F.R.C.P.* — KU Leuven, Belgium
  Open Discussion: Panel and Audience

10:00 A.M.  BREAK

SESSION 5: THE UNCERTAINTIES—WHAT ARE ISSUES SURROUNDING LABORATORY MEASUREMENT OF SERUM 25(OH)D?

10:15 A.M.  Measurement of 25(OH)D: Perspective from the Clinical Lab
  *Andrew Hoofnagle, M.D., Ph.D.* — University of Washington

10:45 A.M.  Panel: What Do These Methodology Issues Mean for Clinical Practice?
  Moderator: *Paul M. Coates, Ph.D.* — ODS, NIH
  - *J. Sanford Schwartz, M.D.* — Wharton University of Pennsylvania
  - *John F. Aloia, M.D.* — Winthrop University Hospital and SUNY Stony Brook
  - *Ian S. Young, Ph.D.* — Queen's University Belfast and Centre for Public Health
  Open Discussion: Panel and Audience
SESSION 6: WHAT CAN WE SAY ABOUT TRANSLATING EVIDENCE INTO CLINICAL PRACTICE AND THE RELATED RESEARCH NEEDS?

11:15 A.M. Panel Discussion: What Did We Hear and What Are the Next Steps?
Moderator: Clifford Rosen, M.D. — Maine Medical Center Research Institute
• Bess Dawson-Hughes, M.D. — Tufts University
• Victor M. Montori, M.D. — Mayo Clinic
• Michael L. LeFevre, M.D., M.S.P.H. — University of Missouri

Open Discussion: Panel and Audience

12:00 NOON CLOSING COMMENTS AND ADJOURN